Experimental investigation of the growth suppression effects of aspirin on HER-2-positive breast cancer cells revealed that aspirin could effectively inhibit human HER-2-positive breast cancer cell viability in a dose-dependent manner; the IC50 values for AU-565 and BT-474 were 5 mM (Figure 1A). Here, ERBB2 is linked to breast carcinoma.